PMID- 29910156
OWN - NLM
STAT- MEDLINE
DCOM- 20190920
LR  - 20190920
IS  - 1873-5126 (Electronic)
IS  - 1353-8020 (Linking)
VI  - 56
DP  - 2018 Nov
TI  - Adverse events with botulinum toxin treatment in cervical dystonia: How much 
      should we blame placebo?
PG  - 16-19
LID - S1353-8020(18)30276-1 [pii]
LID - 10.1016/j.parkreldis.2018.06.017 [doi]
AB  - INTRODUCTION: Botulinum toxin (BoNT) is the first line therapy for cervical 
      dystonia (CD), with most patients receiving many treatment sessions, and so come 
      to recognize and expect the benefits and harms of BoNT, making it difficult to 
      separate which adverse events (AEs) are driven by BoNT and which come from 
      patients' expectations. METHODS: Using the results of three Cochrane systematic 
      reviews of randomized controlled trials (RCTs) we pooled results to calculate the 
      risk of general and specific AEs associated with BoNT, and the proportion of AEs 
      that cannot be pharmacologically attributed to BoNT. RESULTS: Fifteen RCTs, 
      enrolling 1604 patients, were included. BoNT was associated with an increased 
      risk of AEs, but 79% of this increased risk cannot be pharmacologically 
      attributed to BoNT. CONCLUSIONS: Patients with CD attach a considerable 
      expectation of harm due to BoNT, reflected in the large proportion of 
      non-pharmacologically-mediated AEs.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Duarte, Goncalo S
AU  - Duarte GS
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, 
      Universidade de Lisboa, Lisbon, Portugal; Instituto de Medicina Molecular, 
      Lisbon, Portugal; Center for Evidence-Based Medicine, Faculty of Medicine, 
      University of Lisbon, Lisbon, Portugal. Electronic address: gduarte@campus.ul.pt.
FAU - Rodrigues, Filipe B
AU  - Rodrigues FB
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, 
      Universidade de Lisboa, Lisbon, Portugal; Instituto de Medicina Molecular, 
      Lisbon, Portugal; Huntington's Disease Centre, University College London, UK.
FAU - Ferreira, Joaquim J
AU  - Ferreira JJ
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, 
      Universidade de Lisboa, Lisbon, Portugal; Instituto de Medicina Molecular, 
      Lisbon, Portugal; CNS - Campus Neurologico Senior, Torres Vedras, Portugal.
FAU - Costa, Joao
AU  - Costa J
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, 
      Universidade de Lisboa, Lisbon, Portugal; Instituto de Medicina Molecular, 
      Lisbon, Portugal; Center for Evidence-Based Medicine, Faculty of Medicine, 
      University of Lisbon, Lisbon, Portugal; Portuguese Collaborating Centre of the 
      IberoAmerican Cochrane Network-Cochrane Portugal Faculty of Medicine, University 
      of Lisbon, Lisbon, Portugal.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180615
PL  - England
TA  - Parkinsonism Relat Disord
JT  - Parkinsonism & related disorders
JID - 9513583
RN  - 0 (Anti-Dyskinesia Agents)
RN  - 0 (Neuromuscular Agents)
RN  - 0Y70779M1F (rimabotulinumtoxinB)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
SB  - IM
MH  - Anti-Dyskinesia Agents/adverse effects/therapeutic use
MH  - Botulinum Toxins, Type A/*adverse effects/therapeutic use
MH  - Deglutition Disorders/chemically induced
MH  - Humans
MH  - Muscle Weakness/chemically induced
MH  - Neuromuscular Agents/administration & dosage/*adverse effects
MH  - Placebo Effect
MH  - Randomized Controlled Trials as Topic/methods
MH  - Torticollis/diagnosis/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse events
OT  - Botulinum toxin
OT  - Cervical dystonia
OT  - Meta-analysis
OT  - Placebo effect
EDAT- 2018/06/19 06:00
MHDA- 2019/09/21 06:00
CRDT- 2018/06/19 06:00
PHST- 2018/02/15 00:00 [received]
PHST- 2018/05/23 00:00 [revised]
PHST- 2018/06/09 00:00 [accepted]
PHST- 2018/06/19 06:00 [pubmed]
PHST- 2019/09/21 06:00 [medline]
PHST- 2018/06/19 06:00 [entrez]
AID - S1353-8020(18)30276-1 [pii]
AID - 10.1016/j.parkreldis.2018.06.017 [doi]
PST - ppublish
SO  - Parkinsonism Relat Disord. 2018 Nov;56:16-19. doi: 
      10.1016/j.parkreldis.2018.06.017. Epub 2018 Jun 15.